Cautious stance maintained, despite performance upgrade
25/11/21 -"Despite all the good work so far by Novo’s management, we maintain our cautious stance on the Danish diabetes giant. Lack of (medium-term) growth drivers outside the maturing diabetes market, ..."
Pages
75
Language
English
Published on
25/11/21
You may also be interested by these reports :
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...
07/11/25
All segments performed decently in Q3, though the markets were spooked by Hikma’s mid-term outlook downgrade. Operational delays at the Bedford ...
07/11/25
Novonesis delivered a good Q3 2025, with revenue and adjusted EBITDA beating consensus. Organic sales growth of 6% was driven by broad-based volume ...
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...